Addex Therapeutics Ltd ADR (NASDAQ: ADXN)’s stock price has dropped by -53.17 in relation to previous closing price of 16.10. Nevertheless, the company has seen a loss of -60.89% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-19 that Geneva, Switzerland, April 19, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 – 23, 2024 at the Congress Center in Basel, Switzerland.
Is It Worth Investing in Addex Therapeutics Ltd ADR (NASDAQ: ADXN) Right Now?
The stock has a 36-month beta value of 1.58.
The public float for ADXN is 0.79M, and at present, short sellers hold a 2.75% of that float. On April 30, 2024, the average trading volume of ADXN was 17.31K shares.
ADXN’s Market Performance
ADXN stock saw a decrease of -60.89% in the past week, with a monthly decline of -41.09% and a quarterly a decrease of -27.92%. The volatility ratio for the week is 13.91%, and the volatility levels for the last 30 days are 14.65% for Addex Therapeutics Ltd ADR (ADXN). The simple moving average for the past 20 days is -62.30% for ADXN’s stock, with a -22.77% simple moving average for the past 200 days.
ADXN Trading at -48.07% from the 50-Day Moving Average
After a stumble in the market that brought ADXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.97% of loss for the given period.
Volatility was left at 14.65%, however, over the last 30 days, the volatility rate increased by 13.91%, as shares sank -42.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.19% lower at present.
During the last 5 trading sessions, ADXN fell by -60.89%, which changed the moving average for the period of 200-days by -33.91% in comparison to the 20-day moving average, which settled at $19.73. In addition, Addex Therapeutics Ltd ADR saw 24.63% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ADXN
Current profitability levels for the company are sitting at:
- -6.37 for the present operating margin
- -3.3 for the gross margin
The net margin for Addex Therapeutics Ltd ADR stands at -6.54. The total capital return value is set at -5.88. Equity return is now at value -352.80, with -162.63 for asset returns.
Based on Addex Therapeutics Ltd ADR (ADXN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -23.21. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is -475.83.
Currently, EBITDA for the company is -9.91 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 3.57. The receivables turnover for the company is 10.66for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.46.
Conclusion
To sum up, Addex Therapeutics Ltd ADR (ADXN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
